Current clinical trials for the proteasome inhibitor PS-341

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2000年 / 14卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1589 / +
页数：5
相关论文
共 50 条
  • [21] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [22] The proteasome inhibitor PS-341 is more cytotoxic in myeloma cells adhered to fibronectin.
    Landowski, TH
    Adams, J
    Dalton, WS
    [J]. BLOOD, 2002, 100 (11) : 393B - 393B
  • [23] Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou, W
    Yue, P
    Lin, N
    He, M
    Zhou, ZM
    Lonial, S
    Khuri, FR
    Wang, BH
    Sun, SY
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 273 - 280
  • [24] The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Fanourakis, G
    Chauhan, D
    Munshi, NC
    Hideshima, T
    Anderson, KC
    [J]. BLOOD, 2002, 100 (11) : 815A - 815A
  • [25] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [26] Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Lara, PN
    Davies, AM
    Mack, PC
    Mortenson, MM
    Bold, RJ
    Gumerlock, PH
    Gandara, DR
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 40 - 46
  • [27] The proteasome inhibitor PS-341 inhibits the growth of metastatic human prostate cancer in bone.
    Whang, PG
    Iglesias, RC
    Gates, JJ
    Lieberman, JR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S411 - S411
  • [28] Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts
    Nawrocki, ST
    Bruns, CJ
    Harbison, MT
    Bold, RJ
    Gotsch, BS
    Abbruzzese, JL
    Elliott, P
    Adams, J
    McConkey, DJ
    [J]. MOLECULAR CANCER THERAPEUTICS, 2002, 1 (14) : 1243 - 1253
  • [29] Proteasome inhibition by PS-341: A phase I study.
    Hamilton, A
    Eder, JP
    Pavlick, A
    Clark, JW
    Chachoua, A
    Ryan, DP
    Farrell, K
    Wasserstrom, H
    Liebes, L
    Wright, J
    Elliott, P
    Adams, J
    Muggia, F
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
  • [30] Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341
    Lee, C
    Waldman, T
    [J]. CANCER BIOLOGY & THERAPY, 2003, 2 (06) : 700 - 701
12345